• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Veterinary Dentistry >Alendronate Binds to Tooth Root Surfaces and Inhibits Progression of Feline Tooth Resorption: A Pilot Proof-of-Concept Study
【24h】

Alendronate Binds to Tooth Root Surfaces and Inhibits Progression of Feline Tooth Resorption: A Pilot Proof-of-Concept Study

机译：阿仑膦酸盐与牙齿根部表面结合并抑制猫牙齿吸收的进行：概念验证研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tissue distribution, bioavailability, and efficacy of alendmnate in preventing progression ofresorption of teeth were evaluated in cats. [Butyl-4-~(14)C-]-alendmnate accumulates on subgingival tooth and alveolar bone surfaces adjacent to vascularizedtissue resulting in concentration of the drug around tooth roots. Three cats were treated with a 0.03 mg/kg IVbolus of [butyi-4-~(14)C-]-alendronate followed by blood, urine, and feces collection and euthanasia 24-hours later. Drug tissue distribution was accessed by autoradiography and sample combustion. To assess bioavailability, 12 cats were administered alendmnate orally (3.0 or 9.0 mg/kg in water or 9.0 mg/kg in tuna water) and urine was collected for 24-hours. In these formulations, alendmnate oral bioavailability in cats was approximately 3%. In addition, 10 cats with radiographic evidence of pre-existing tooth resorption (14 affected teeth) were treated with vehicle or 3.0 mg/kg alendmnate per os once weekly for 22-weeks and, then, 9.0 mg/kg per os twice weekly for 27-weeks in a random, masked study. Radiographic area of resorption was measured and progression scored every 3 to 4-months. In placebo-treated cats, resorption progressed in five of six teeth (+ 97% average increase in area of resorption), whereas progression ofresorption was seen in only three of eight affected teeth in alendronate-treated cats with a - 22% average change (decrease) in area (P < 0.01 difference in number of teeth showing progression; P < 0.001 difference in areaofresorption). Alendronate accumulated preferentially on subgingival tooth surfaces and adjacent alveolar bone and, at a dose of 9 mg/kg twice weekly, effectively slowed or arrested the progression ofresorption.
机译：在猫中评估了阿仑膦酸钠的组织分布，生物利用度和预防牙齿吸收进展的功效。 [Butyl-4-〜（14）C-]-alendmnate累积在龈下牙齿和与血管化组织相邻的牙槽骨表面，导致药物在牙根周围集中。对三只猫用0.03 mg / kg的[butyi-4-〜（14）C-]-阿仑膦酸钠静脉注治疗，然后在24小时后收集血液，尿液和粪便并实施安乐死。通过放射自显影和样品燃烧获得药物组织分布。为了评估生物利用度，对12只猫口服阿仑膦酸盐（水中分别为3.0或9.0 mg / kg或金枪鱼水中为9.0 mg / kg），并收集尿液24小时。在这些制剂中，阿仑膦酸钠在猫中的口服生物利用度约为3％。此外，每周对10只有放射线影像学证据的猫（已有14只受影响的牙齿）进行放射治疗，每周一次用赋形剂或3.0 mg / kg阿仑膦酸钠/ os每周治疗22周，然后每周两次用9.0 mg / kg os / os进行两次治疗。在一项随机的，隐蔽的研究中为期27周。每3到4个月测量一次放射学的吸收区，并对进展进行评分。在接受安慰剂治疗的猫中，六颗牙齿中有五颗的牙齿进行了吸收（平均吸收面积增加了97％），而在经过阿仑膦酸盐治疗的猫中，只有八分之三的患牙中出现了吸收的进展，平均变化率为-22％（减少（P <0.01齿数差异显示进展; P <0.001齿吸收面积差异）。阿仑膦酸盐优先积聚在龈下牙齿表面和邻近的牙槽骨上，并且每周两次两次以9 mg / kg的剂量有效地减缓或阻止了吸收的进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号